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Abstract
Purpose Fatigue is a cancer-related symptom with great
impact on patients’ daily lives, but often not discussed with
their oncologists. This survey explored functional and psy-
chological fatigue impact among different cancer symp-
toms according to patient’s perception (pp).
Methods A cross-sectional, self-administered survey was
conducted in 10 oncologist services throughout Spain. De-
mographical data and tumour diagnoses were collected. Fa-
tigue impact on functional and social activities (Likert
scale) and on emotional well-being (visual analogue scale)
was measured. The pp of oncologist’s response to fatigue
report was recorded.
Results 505 surveyed cancer patients were analysed (55.2%
women, aged 58.8 years ±11.7), 97.8% remembered experi-
encing fatigue during treatment. 27.1% did not discuss their
fatigue with their oncologist. Fatigue affected patient’s daily
routine (≥50% of times) included self-care (58.26%), enter-
tainment activities (69.8%), and relationships (71.4%). Fa-
tigue was the most bothersome symptom of cancer.
Conclusions Cancer patients perceive fatigue as the symp-
tom with highest impact on their daily living and that sub-
stantially affects their emotional and social areas.
Keywords Quality of life · Fatigue · Cancer · Outcome
assessment · Patient-professional relations
Introduction 
Fatigue is a complex, multifactor disorder that affects the
physical and psychological wellbeing of cancer patients
and, therefore, cancer-related fatigue (CRF) has been asso-
ciated with significant impairment of patients’ quality of
life [1].
Most patients with CRF feel unable to lead a normal
life [2] and have to limit their social activities and family
relationships. Fatigue has an even deeper impact on their
quality of life than other symptoms such as pain, depres-
sion and nausea [3–5].
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Two US surveys conducted by the Fatigue Coalition [6]
documented the high prevalence of fatigue in patients suf-
fering from cancer (76–78%) [7, 8], but perhaps the most
notable outcome was the disagreement in fatigue percep-
tion between patients and oncologists (61% of the patients
felt that their daily living was more affected by fatigue than
by cancer-related pain, while only 37% of oncologists be-
lieved that this was the patient’s situation). Almost all pa-
tients felt that CRF was a significant emotional component
that contributed to perceiving a more serious loss of control
and the inability to lead a normal life, which often provoked
feelings of sadness, frustration, motivation loss and mental
exhaustion [9]. This emotional impact, mentioned above,
has been corroborated by numerous studies [10–12].
Moreover, an improvement in the management of fa-
tigue may lead to an improvement in cancer-provoked psy-
chological disturbances such as depression or anxiety [13].
As there are no Spanish studies on this, this survey was
designed with the aim of better understanding how Spanish
patients perceive their disease-related fatigue. The purpose
of this investigation was to examine how patients assess fa-
tigue impact on their moods, personal activities and social
relationships, and the fatigue load in relation to other can-
cer symptoms according to the patient’s perception (pp).
Material and methods
Design
A cross-sectional multi-centre survey was conducted from
August to October 2007 in 10 medical oncology departments
throughout Spain. Each survey contained written instructions
and clearly specified that the filling out of the form was both
voluntary and confidential. Responses were handwritten by
patients in the oncologist waiting room and were not super-
vised during the completion and return of the survey.
Patients
Respondents anonymously completed this self-adminis-
tered survey. Eligible patients were ≥18 years of age, hav-
ing cancer diagnosis and their last treatment regimen (ra-
diotherapy and/or chemotherapy) between 2 and 12 months
before completing the survey. Patients with dementia or
any other serious mental illness that prevented survey com-
prehension were excluded. 
Survey
The survey instrument consisted of 12 items. Data on de-
mographic and clinical characteristics were collected for
statistical purposes.
The survey included a 10-mm visual analogue scale
(VAS) to measure the fatigue impact on emotional wellbe-
ing during cancer treatment (anchored by two extremes:
from ‘0’=not at all to ‘100’=very much). The survey also
included 3 questions regarding fatigue impact on daily liv-
ing activities, including functional and social activities,
each one rated on a 5-point Likert scale (from ‘5’=always
to ‘0’=never).
Two additional questions gathered the pp of the fatigue
treatment decision-making process. Patients were asked if
they discussed the fatigue treatment with their physician,
and if they had received any treatment for reducing fatigue. 
Finally, patients were asked to fill out a check-list with
the 3 side effects or symptoms that most affected their daily
living (ranking from 1=the most bothersome to 3=the third
one) among 10 side effects/symptoms: anxiety, fatigue,
anorexia, hair loss, depression, diarrhoea, pain, constipa-
tion, sleep disturbances, weight loss and nausea/vomiting. 
Statistical analyses
Descriptive statistics were used to summarise demographic
data and survey responses. Absolute frequencies were pre-
sented for categorical data, and mean and standard devia-
tion (SD) were used for quantitative data. Additional de-
scriptive analyses were performed grouping patients by sex
or by cancer type.
All patients who had returned a completed survey were
included in the analysis set. The statistics were generated
using a standard statistical package (SPSS for Windows,
version 13.0, SPSS Inc, Chicago, IL, USA). 
Results
Clinical characteristics
527 completed questionnaires were returned from 10 cen-
tres and 505 respondents were included in the evaluable
analysis set; 55.2% of them were women and the median
age was 60 years (range 28–87). The most prevalent tu-
mours were located in breast (26.5%), gastrointestinal
(20.8%) and lung (14.5%). 77.0% of patients had undertak-
en chemotherapy, 1.4% radiotherapy and 21.4% both (with
and without other additional treatment) (Table 1).
Fatigue prevalence
97.8% of the patients remembered experiencing fatigue
during the course of their cancer treatment at least once
(80.2% at least 50% of the time) (Table 2). 
Patients’ perception of fatigue management
72.9% of surveyed patients reported that they discussed fa-
tigue treatments with their physicians. 61.2% of the pa-
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tients remembered receiving some treatment for fatigue re-
duction. 16.8% of those who asked for some treatment re-
ported that nothing was recommended by the oncologist. 
Fatigue impact
The impact of fatigue on emotional wellbeing showed a
mean on the VAS of 54.87 (SD: 19.2). At least 50% of the
time, 58.3% of patients informed that fatigue limited their
self-care activities (washing self, dressing or undressing
self, etc.); 69.8% also reported that fatigue affected their
leisure activities (walking, shopping, going to a movie,
etc.) and in 71.4% of the patients, fatigue prevented them
from conducting social activities with friends and relatives
(Fig. 1).
Fatigue was remembered by patients as the most both-
ersome cancer symptom or side effect. 63.4% of the pa-
tients identified it as the first-, second- or third-ranking
symptom from a list of the 10 most frequent cancer-related
symptoms. In patients grouped according to sex or tumour
type, fatigue remained the symptom that most affected
their daily lives during treatment (Table 3).
Discussion 
To our knowledge these is the first data about fatigue
prevalence and impact in cancer patients within the Span-
ish population. These findings are consistent with those of
previous studies conducted in other countries.
A higher percentage of patients than other epidemio-
logical studies [3, 6, 7] reported receiving some treatment
to reduce fatigue. This pattern of findings must be viewed
in light of the study’s methodology limitations. The study
relied on self-administered surveys and did not consider
numerous variables possibly important in providing a
thorough understanding regarding CRF management.
Furthermore, this study did not assess different types of
prescribed measures for reducing fatigue such as medica-
tion (erythropoietic agents, iron and vitamin supplements,
etc.) or lifestyle recommendations. Despite these method-
ological limitations, research suggests that fatigue is re-
membered by patients as the most bothersome cancer
symptom. In this study, fatigue was found as the main
symptom in the ranking of disabling cancer symptoms. It
even rises far above the second most annoying symptom,
anxiety.
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Table 1 Patients’ characteristics
Total (n=505) Men (n=226) Women (n=279)
Gender (%) 44.8 55.2
Age (years): mean (SD) 58.8 (1.7) 61.5 (10.8) 56.7 (12.0)
Type of cancera % (n)
Breast 26.5 (134) – 48.0 (134)
Gastrointestinal 20.8 (105) 23.9 (54) 18.3 (51)
Lung 14.5 (73) 25.2 (57) 5.7 (16)
Prostate 8.3 (42) 18.6 (42) –
Leukaemia/lymphoma 8.1 (41) 8.0 (18) 8.2 (23)
Bladder/kidney/genitourinary 6.1 (31) 7.5 (17) 5.0 (14)
Head/neck 6.7 (34) 12.8 (29) 1.8 (5)
Gynaecologic 8.1 (41) – 14,7 (41)
Unknown 2.4 (12) 5.3 (12) –
Type of treatmenta
Chemotherapy 98.4 (497) 98.2 (222) 98.6 (275)
Radiotherapy 22.8 (115) 19.0 (43) 25.8 (72)
Surgery 27.5 (139) 17.3 (39) 35.8 (100)
Others 2.6 (13) 2.7 (6) 2.5 (7)
Number of treatments: mean (SD) 1.5 (0.76) 1.4 (0.6) 1.6 (0.9)
aSome patients recorded more than one type
Table 2 Characteristics of fatigue: prevalence and impact on emotional wellbeing
Total (n=505) Men (n=226) Women (n=279)
How often did you feel fatigue during the treatment?: % (n) 100.0(504) 100.0 (225) 100.0 (279)
Always 4.4 (22) 3.6 (8) 5.0 (14)
Many times 26.2 (132) 29.8 (67) 23.3 (65)
50% of the times 49.6 (250) 44.4 (100) 53.8 (150)
Hardly ever 17.3 (87) 19.1 (43) 15.8 (44)
Never 2.6 (13) 3.1 (7) 2.2 (6)
Fatigue impact on emotional well-being: VAS mean (SD) 54.9 (19.2) 55.5 (19.5) 54.4 (19.0)
Although the data were not confirmed by statistical
tests, the results suggest differences between genders in the
assessment of symptoms. There are few research studies on
gender differences in cancer-related pain, fatigue and de-
pression. No differences were found either in pain or in fa-
tigue, but prevalence rates for depression were higher in
women [14]. The assessment of cancer symptoms has sub-
jective components linked to gender, psychological and so-
cial aspects [15–17]. Even so, fatigue remained the most
limiting cancer side effect or symptom for both genders.
Pain has traditionally been the most evaluated symptom
and therefore the most treated by physicians [18], probably
because it has ceased to be a concern for most patients.
Our data, along with those from similar studies, suggest the
need for health professionals to take into account the psy-
chological and social impact of inadequate fatigue manage-
ment [19].
An objective quantification of fatigue impact on cancer
patients is not easy. This can be limiting for a fair assess-
ment by the oncologist [20]. In this respect, it would be
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Table 3 Impact of fatigue relative to other side effects/symptoms by sex or by tumour
“Rank the three symptoms that you remember Symptoms rank
a by sexes
affecting your daily life the most Total (n=505) Men (n=226) Women (n=279)
Fatigue 1st (63.4%) 1st (60.6%) 1st (65.6%)
Anxiety 2nd (49.9%) 3rd (48.2%) 2nd (51.3%)
Sleep disturbances 3rd (36.0%) 2nd (48.7%) –
Nausea/vomiting 4th (29.5%) – –
Anorexia 5th (29.1%) – –
Depression 6th (28.7%) – –
Hair loss 7th (28.3%) – 3rd (42.7%)
“Rank the three symptoms that you remember Symptoms rank
a by tumour typeb
affecting your daily life the most” Total (n=505) Breast (n=134) Lung (n=73) Gastrointestinal (n=105)
Fatigue 1st 1st (62.2%) 1st (83.6%) 1st (58.1%)
Anxiety 2nd 2nd (54.5%) 2nd (56.2%) –
Sleep disturbances 3rd – 3rd (43.8%) 3rd (42.9%)
Nausea/vomiting 4th – – –
Anorexia 5th – – 2nd (47.6%)
Depression 6th 3rd (21.9%) – –
aRank based on 3 possible responses: 1 (the most bothersome symptom), 2 (the second one) and 3 (the third one)




















Always Many times 50% of the times Hardly ever NeverHow often did 
fatigue prevent you 
from …..?
Fig. 1 Impact of fatigue on patient’s daily living (N=505)
(1): spending time with family members, friends, or neighbours, playing with children, participating in family
parties, etc. (2): walking, shopping, going to a movie or a restaurant, etc. (3): washing self, dressing/undressing
self, etc
necessary to have some psychometric tools to assist the
physician in measuring fatigue severity to provide a better
understanding of the clinical implications of fatigue and
make its management more appropriate.
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